Skip to main content
. 2006 Jul 17;63(12):836–843. doi: 10.1136/oem.2006.027995

Table 1 Frequency of chronic bronchitis symptoms and average of air pollutants (outdoor home NO2 and city average PM2.5 and S) by centre.

Centre* n Prevalence at ECRHS‐I Prevalence at ECRHS‐II New onset† at ECRHS‐II n NO2 (μg/m3) Range PM2.5 (μg/m3) S (ng/m3)
Chronic phlegm Productive chronic cough Chronic phlegm Productive chronic cough Chronic phlegm Productive chronic cough
Erfurt (C) 287 2.75 1.94 3.48 3.07 1.89 1.99 0 16.3 1144.3
Turin (S) 123 7.79 2.47 3.25 0.85 3.57 0.86 72 70.81 (35–136) 44.9 1827.4
Antwerp City (C) 299 9.61 6.07 7.82 4.25 4.28 3.25 52 47.79 (28–78) 24.1 1464.7
Basel (C) 459 3.43 2.03 3.28 2.06 2.48 1.42 89 34.62 (18–69) 17.4 1038.9
Norwich (C) 257 3.85 1.51 5.49 2.55 3.51 2.17 118 25.69 (9.2–74) 16.2 977.4
Verona (S) 205 2.92 1.17 2.94 0.53 2.55 0.53 121 52.52 (9.4–110) 41.5 2015.2
Tartu (N) 259 5.61 3.07 4.63 0.00 2.76 0.00 37 22.90 (14–37) 14.8 892.0
South Antwerp (C) 340 4.32 1.98 3.56 1.27 2.29 1.29 86 35.27 (23–57) 20.8 1453.5
Pavia (S) 192 8.80 4.96 4.17 3.85 1.92 1.91 87 43.12 (18–86) 35.3 1782.6
Paris (S) 433 6.00 3.71 6.26 3.46 3.53 2.54 0 17.8 1080.5
Oviedo (S) 242 8.73 4.51 10.74 5.21 6.51 1.99 135 45.61 (12–143) 15.9 1181.2
Ipswich (C) 297 5.19 3.22 6.42 3.32 4.78 2.07 82 30.09 (0.34–69) 16.5 998.6
Barcelona (S) 272 5.61 2.3 7.12 1.24 6.58 1.26 125 76.86 (41–146) 22.2 1387.9
Albacete (S) 308 14.02 7.59 9.09 4.64 4.69 3.09 142 36.88 (7.1–125) 13.1 1008.5
Goteborg (N) 505 9.38 3.81 7.54 3.82 4.13 2.75 0 12.6 903.4
Galdakao (S) 360 6.79 2.06 8.06 3.65 6.71 3.1 176 40.55 (5.8–102) 16.3 1584.5
Huelva (S) 204 14.76 5.54 11.76 8.52 5.42 5.95 59 35.34 (13–98) 17.3 1557.8
Umea (N) 421 8.17 4.17 6.7 2.08 4.59 1.07 171 6.03 (0.34–20) 5.6 414.8
Grenoble (S) 384 5.51 2.12 5.21 3.03 3.5 1.97 0 19.0 887.7
Reykjavik (N) 460 5.21 2.33 5.9 1.71 4.51 1 82 12.82 (0.34–29) 3.7 155.3
Uppsala (N) 517 6.47 2.81 4.66 1.47 3.27 1.31 0 10.4 752.1
Total 6824 6.53 3.20 6.07 2.80 3.96 1.93 1634 38.22 (0.34–146) 19.12 1167.07

*Ordered by participation rate in the follow up.

†New onset among those without these symptoms at baseline.

Geographical area: N, North; C, Centre; S, South.